SLC5A2 and diabetes mellitus: Among patients with diabetes inadequately controlled by metformin, SGLT2 inhibition reduced circulating biomarkers of inflammation and fibrosis compared to treatment with the insulin secretagogue glimepiride in 1–2 years follow up.